从最初的螨过敏症状到螨特异性免疫疗法的漫长道路

Q3 Medicine

Allergo Journal International Pub Date : 2022-10-19 DOI:10.1007/s40629-022-00230-9

Norbert Mülleneisen MD, Manfred Springob, Stephanie Salge, Annika Völkel, Friederike Magnet, Jens Callegari

{"title":"从最初的螨过敏症状到螨特异性免疫疗法的漫长道路","authors":"Norbert Mülleneisen MD, Manfred Springob, Stephanie Salge, Annika Völkel, Friederike Magnet, Jens Callegari","doi":"10.1007/s40629-022-00230-9","DOIUrl":null,"url":null,"abstract":"<div><h2>Summary</h2><div><p>The path from first symptoms to initiation of allergen-specific immunotherapy (AIT) is too long in our survey, at just under 12 years. Even from diagnosis to AIT, it still takes 8.5 years. The reasons are manifold. The complaints are mostly sneezing (75%), runny and stuffy nose (65 and 63%, respectively), itching of the eyes and nose (59%), but also breathing difficulties (40%). Most of our patients were polysensitized (78%) and had asthma (63%). AIT should be considered earlier in mite allergic patients.</p></div></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"31 8","pages":"284 - 287"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"The long road from the first symptoms of mite allergy to mite-specific immunotherapy\",\"authors\":\"Norbert Mülleneisen MD, Manfred Springob, Stephanie Salge, Annika Völkel, Friederike Magnet, Jens Callegari\",\"doi\":\"10.1007/s40629-022-00230-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h2>Summary</h2><div><p>The path from first symptoms to initiation of allergen-specific immunotherapy (AIT) is too long in our survey, at just under 12 years. Even from diagnosis to AIT, it still takes 8.5 years. The reasons are manifold. The complaints are mostly sneezing (75%), runny and stuffy nose (65 and 63%, respectively), itching of the eyes and nose (59%), but also breathing difficulties (40%). Most of our patients were polysensitized (78%) and had asthma (63%). AIT should be considered earlier in mite allergic patients.</p></div></div>\",\"PeriodicalId\":37457,\"journal\":{\"name\":\"Allergo Journal International\",\"volume\":\"31 8\",\"pages\":\"284 - 287\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergo Journal International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s40629-022-00230-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergo Journal International","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1007/s40629-022-00230-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

摘要

总结在我们的调查中，从最初出现症状到开始过敏原特异性免疫疗法（AIT）的时间太长，不到12年。即使从诊断到AIT，也需要8.5年的时间。原因是多方面的。投诉主要是打喷嚏（75%）、流鼻涕和鼻塞（分别为65%和63%）、眼睛和鼻子发痒（59%），还有呼吸困难（40%）。我们的大多数患者是多敏症（78%）和哮喘（63%）。对螨过敏的患者应尽早考虑AIT。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The long road from the first symptoms of mite allergy to mite-specific immunotherapy

Summary

The path from first symptoms to initiation of allergen-specific immunotherapy (AIT) is too long in our survey, at just under 12 years. Even from diagnosis to AIT, it still takes 8.5 years. The reasons are manifold. The complaints are mostly sneezing (75%), runny and stuffy nose (65 and 63%, respectively), itching of the eyes and nose (59%), but also breathing difficulties (40%). Most of our patients were polysensitized (78%) and had asthma (63%). AIT should be considered earlier in mite allergic patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Allergo Journal International Medicine-Immunology and Allergy

CiteScore

4.60

自引率

0.00%

发文量

期刊介绍： Allergo Journal International is the official Journal of the German Society for Applied Allergology (AeDA) and the Austrian Society for Allergology and Immunology (ÖGAI). The journal is a forum for the communication and exchange of ideas concerning the various aspects of allergy (including related fields such as clinical immunology and environmental medicine) and promotes German allergy research in an international context. The aim of Allergo Journal International is to provide state of the art information for all medical and scientific disciplines that deal with allergic, immunological and environmental diseases. Allergo Journal International publishes original articles, reviews, short communications, case reports, and letters to the editor. The articles cover topics such as allergic, immunological and environmental diseases, the latest developments in diagnosis and therapy as well as current research work concerning antigens and allergens and aspects related to occupational and environmental medicine. In addition, it publishes clinical guidelines and position papers approved by expert panels of the German, Austrian and Swiss Allergy Societies. All submissions are reviewed in single-blind fashion by at least two reviewers. Originally, the journal started as a German journal called Allergo Journal back in 1992. Throughout the years, English articles amounted to a considerable portion in Allergo Journal. This was one of the reasons to extract the scientific content and publish it in a separate journal. Hence, Allergo Journal International was born and now is the international continuation of the original German journal. Nowadays, all original content is published in Allergo Journal International first. Later, selected manuscripts will be translated and published in German and included in Allergo Journal.